Pacific Biosciences Of California (PACB) Gross Profit (2010 - 2026)

Pacific Biosciences Of California's Gross Profit history runs 17 years deep, the most recent figure standing at $12.8 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 1036.62% year-over-year to $12.8 million in Q1 2026; TTM through Mar 2026 was $60.0 million, a 143.58% increase from a year earlier, with the FY2025 full-year figure at $45.8 million, up 22.79% from the prior year.
• Gross Profit fell to $12.8 million in Q1 2026 per PACB's latest filing, from $16.6 million in the prior quarter.
• Across five years, Gross Profit topped out at $17.9 million in Q3 2023 and bottomed at -$1.4 million in Q1 2025.
• The 5-year median for Gross Profit is $12.8 million (2026), against an average of $11.6 million.
• Across the five-year window, Gross Profit sank 112.15% in 2025 and jumped 1036.62% in 2026, its largest moves.
• Year by year, Gross Profit stood at $5.1 million in 2022, then jumped by 86.21% to $9.6 million in 2023, then grew by 5.09% to $10.1 million in 2024, then surged by 64.7% to $16.6 million in 2025, then declined by 22.49% to $12.8 million in 2026.
• Per Business Quant, the three latest PACB Gross Profit figures stand at $12.8 million (Q1 2026), $16.6 million (Q4 2025), and $15.9 million (Q3 2025).